A new antibody treatment reduced levels of type I interferon-producing cells in patients with cutaneous lupus, improving skin symptoms during phase 1 clinical trials.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.